CancerDrs

Lung Cancer clinical trials in Arizona

40 actively recruiting lung cancer trials at 14 sites across Arizona.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 3 Recruiting NIH

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in Arizona:
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
  • Kingman Regional Medical Center — Kingman, Arizona
  • Cancer Center at Saint Joseph's — Phoenix, Arizona
  • Banner Boswell Medical Center — Sun City, Arizona
  • Banner University Medical Center - Tucson — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…

Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Arizona:
  • Kingman Regional Medical Center — Kingman, Arizona
  • Cancer Center at Saint Joseph's — Phoenix, Arizona
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona
  • Banner University Medical Center - Tucson — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Arizona:
  • Local Institution - 007-556-A — Goodyear, Arizona
  • USOR - Arizona Oncology - Prescott Valley — Prescott Valley, Arizona
  • Local Institution - 007-568-A — Safford, Arizona
  • Local Institution - 007-568-B — Safford, Arizona
  • Local Institution - 007-568-C — Safford, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…

Sponsor: Pfizer
NCT ID: NCT07222566
Sites in Arizona:
  • Pioneer Research Center — Bullhead City, Arizona
  • Ironwood Cancer & Research Centers — Chandler, Arizona
  • Ironwood Cancer & Research Centers — Gilbert, Arizona
  • Ironwood Cancer & Research Centers — Glendale, Arizona
  • Ironwood Cancer & Research Centers — Goodyear, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …

Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Arizona:
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
  • Banner University Medical Center Phoenix — Phoenix, Arizona
  • The University of Arizona Cancer Center - North Campus — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…

Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in Arizona:
  • City of Hope, Phoenix — Phoenix, Arizona
  • The University of Arizona Cancer Center - North Campus — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary en…

Sponsor: Summit Therapeutics
NCT ID: NCT05899608
Sites in Arizona:
  • Banner University Medical Center — Phoenix, Arizona
  • TMC Healthcare — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…

Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Arizona:
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Arizona:
  • Banner MD Anderson Cancer Center ( Site 0181) — Gilbert, Arizona
  • The University of Arizona Cancer Center - North Campus ( Site 0163) — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in Arizona:
  • Southern Arizona VA Health Care System — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemot…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07063745
Sites in Arizona:
  • Mayo Clinic in Arizona - Phoenix — Phoenix, Arizona
  • University of Arizona Cancer Center — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation thera…

Sponsor: Shanghai Junshi Bioscience Co., Ltd.
NCT ID: NCT06095583
Sites in Arizona:
  • Banner MD Anderson Cancer Center — Goodyear, Arizona
  • Banner University Medical Center — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-smal…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06667076
Sites in Arizona:
  • City of Hope Phoenix — Goodyear, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…

Sponsor: AbbVie
NCT ID: NCT06568939
Sites in Arizona:
  • Ironwood Cancer and Research Center /ID# 276370 — Chandler, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

This Phase1/2, open label, multicenter study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with NSCLC having EGFR and/or HER2 mutations. Phase 1 wi…

Sponsor: BlossomHill Therapeutics
NCT ID: NCT06706076
Sites in Arizona:
  • Mayo Clinic Hospital - Arizona — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab…

Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06922591
Sites in Arizona:
  • Mayo Clinic Scottsdale — Scottsdale, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naï…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT04165070
Sites in Arizona:
  • Banner MD Anderson Cancer Center ( Site 0001) — Gilbert, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytological…

Sponsor: BioNTech SE
NCT ID: NCT07070232
Sites in Arizona:
  • Mayo Clinic Arizona — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Arizona:
  • Arizona Oncology Associates, PC - NAHOA — Prescott, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this stud…

Sponsor: Boehringer Ingelheim
NCT ID: NCT05882058
Sites in Arizona:
  • Mayo Clinic-Arizona — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activat…

Sponsor: Carl Allen
NCT ID: NCT04079179
Sites in Arizona:
  • Phoenix Children's Hospital — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.

Sponsor: AstraZeneca
NCT ID: NCT06996782
Sites in Arizona:
  • Research Site — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …

Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Arizona:
  • Banner Health- MD Anderson Cancer Center — Gilbert, Arizona
View on ClinicalTrials.gov →

Showing 25 of 40 trials with sites in Arizona. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15